Clinical correlation of striatal 1H MRS changes in Huntington's disease

被引:81
作者
Sánchez-Pernaute, R
García-Segura, JM
Alba, AD
Viaño, J
de Yébenes, JG
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Neurol, Madrid, Spain
[2] Clin NS del Rosario, Neuroradiol Unit, Madrid, Spain
[3] Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, Madrid, Spain
关键词
proton MRS; Huntington's disease; striatum;
D O I
10.1212/WNL.53.4.806
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To study the clinical significance of metabolic alterations as measured in vivo with proton MRS in the striatum of patients with Huntington's disease (HD). Methods: Localized, single-Troxel MRS was performed on the basal ganglia of 10 HD patients (4 presymptomatic gene carriers and 6 akinetic patients) and 5 age-matched healthy individuals. Metabolite quantification was pet-formed by referring the areas of the respective spectral peaks to that of water in the analyzed voxel. The spectroscopic findings were correlated with motor and cognitive performance in several specific tests and with the length of the CAG repeat expansion normalized for age. Results. N-acetylaspartate (NAA) and creatine were reduced markedly in both groups of patients, particularly in the advanced group (approximately 60%), but the decrease was also significant in presymptomatic patients (approximately 30%) whose motor and cognitive performances were within the normal range. Both metabolites correlated highly with the motor score of the Unified Hunting ton's Disease Rating Scale and with computed measurements of saccadic and tapping speed, Creatine reduction was also well correlated with performance in cognitive timed tasks and with the length of CAG expansion (r = -0.81). Conclusion: The creatine signal appears to be an interesting marker for progression in HD and could be useful in assessing therapeutic outcome, particularly during the initial stages when most clinical indices are still within the normal range.
引用
收藏
页码:806 / 812
页数:7
相关论文
共 41 条
[1]
[Anonymous], 1968, Learn Disord, DOI DOI 10.1080/13803390591004428
[2]
[11C]raclopride-PET studies of the Huntington's disease rate of progression:: Relevance of the trinucleotide repeat length [J].
Antonini, A ;
Leenders, KL ;
Eidelberg, D .
ANNALS OF NEUROLOGY, 1998, 43 (02) :253-255
[3]
AYLWARD EH, 1991, AM J NEURORADIOL, V12, P1217
[4]
Longitudinal change in basal ganglia volume in patients with Huntington's disease [J].
Aylward, EH ;
Li, Q ;
Stine, OC ;
Ranen, N ;
Sherr, M ;
Barta, PE ;
Bylsma, FW ;
Pearlson, GD ;
Ross, CA .
NEUROLOGY, 1997, 48 (02) :394-399
[5]
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease [J].
Aylward, EH ;
Codori, AM ;
Barta, PE ;
Pearlson, GD ;
Harris, GJ ;
Brandt, J .
ARCHIVES OF NEUROLOGY, 1996, 53 (12) :1293-1296
[6]
REDUCED BASAL GANGLIA VOLUME ASSOCIATED WITH THE GENE FOR HUNTINGTONS-DISEASE IN ASYMPTOMATIC AT-RISK PERSONS [J].
AYLWARD, EH ;
BRANDT, J ;
CODORI, AM ;
MANGUS, RS ;
BARTA, PE ;
HARRIS, GJ .
NEUROLOGY, 1994, 44 (05) :823-828
[7]
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes [J].
Bäckman, L ;
Robins-Wahlin, TB ;
Lundin, A ;
Ginovart, N ;
Farde, L .
BRAIN, 1997, 120 :2207-2217
[8]
BICAUDATE INDEX IN COMPUTERIZED TOMOGRAPHY OF HUNTINGTON DISEASE AND CEREBRAL ATROPHY [J].
BARR, AN ;
HEINZE, WJ ;
DOBBEN, GD ;
VALVASSORI, GE ;
SUGAR, O .
NEUROLOGY, 1978, 28 (11) :1196-1200
[9]
Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length [J].
Becher, MW ;
Kotzuk, JA ;
Sharp, AH ;
Davies, SW ;
Bates, GP ;
Price, DL ;
Ross, CA .
NEUROBIOLOGY OF DISEASE, 1998, 4 (06) :387-397
[10]
BENITEZ J, 1994, HUM GENET, V94, P563